0001193125-26-220645
SEC filingQ1 losses and cash burn intensified due to increased clinical investments and headcount growth, partially offset by ATM financing that extends cash runway into late 2028.
Cash burn intensified, with net cash provided by operating activities at -$32.6 million compared to -$25.5 million prior year, aligning with the larger net loss though mitigated by non-cash adjustments. Capital expenditures rose modestly to $88 thousand from $14 thousand. Despite accelerated burn, management affirms that cash, cash equivalents, and marketable securities as of March 31, 2026 will fund operating expenses and capital expenditures into the second half of 2028 under the current operating plan. ATM financing bolstered liquidity, countering the investment-driven outflows.
Looking forward, Tyra expects G&A expenses to continue increasing to support growing R&D, manufacturing, and public company costs. This positions the company to sustain clinical momentum while managing cash through disciplined deployment of financing proceeds.